

INFORMATION DISCLOSURE

To: - State Securities Commission

- Hanoi Stock Exchange

1. Name of Organization: **MEDIPLANTEX NATIONAL PHARMACEUTICAL
JOINT STOCK COMPANY**

- Securities code: MED

- Address: 358 Giai Phong, Phuong Liet, Ha Noi

- Person responsible for information disclosure: Mr. Mai Nhat Thanh

Type of disclosed information: Periodic ☒ Extraordinary Upon request

2. Contents of disclosure:

- Notice of the record date for the exercise of rights to attend the 2026 Annual General Meeting of Shareholders

3. This information was published on the company's website on 13/05/2026, as in the link:
<http://www.mediplantex.com/cổ-đông/công-bố-thông-tin.html>

We hereby certify that the information provided is true and correct and we bear the full responsibility to the law.

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JSC
GENERAL DIRECTOR**



Mai Nhat Thanh

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JOINT STOCK
COMPANY**

No.: 15/2026/CV-MP
RE: THE RECORD DATE FOR THE
EXERCISE OF RIGHTS

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom - Happiness

Ha Noi, May 13, 2026

NOTICE

**(Regarding the record date for the exercise of rights to attend
the 2026 Annual General Meeting of Shareholders)**

To: Viet Nam Securities Depository and Clearing Corporation

Name of Issuing Organization: Mediplantex National Pharmaceutial JSC
Transaction Name: Mediplantex National Pharmaceutial JSC
Headquarters: 358 Giai Phong, Phuong Liet, Ha Noi
Tel: (84-4) 3864 1552

**We hereby notify the Vietnam Securities Depository and Clearing Corporation
(VSDC) of the record date to establish the list of holders for the following securities:**

Name of securities: **Shares of Mediplantex National Pharmaceutial JSC**
Securities code: **MED**
Type of securities: Common shares
Par value: VND 10,000/share
Stock exchange: UPCOM
Record date: **May 28, 2026**

**1. Reason and Purpose: To attend the 2026 Annual General Meeting of
Shareholders**

2. Detailed content:

- Execution ratio: 01 share – 01 voting right
- Execution time: Expected on Friday, June 26, 2026
- Venue: The Board of Directors will notify shareholders of the venue in the invitation letter to attend the General Meeting of Shareholders. The Company will also publish the information on its website at www.mediplantex.com.

- Meeting agenda: Matters under the authority of the General Meeting of Shareholders (details will be specified in the meeting materials sent to shareholders)

We request VSDC to establish and send the list of securities holders as of the aforementioned record date to our Company via VSDC's electronic communication portal.

Recipients:

- As above;
- Stock Exchange;
- Archived at the Company

*** Attached documents:**

- Resolution No. 03/2026/NQ-HDQT

**LEGAL REPRESENTATIVE
GENERAL DIRECTOR**



Mai Nhat Thanh

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JOINT STOCK
COMPANY**

No.: 03/ 2026 / NQ- HĐQT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

Hanoi, May 7, 2026

**RESOLUTION
OF THE BOARD OF DIRECTORS**

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

- Pursuant to Law on Enterprises of the Socialist Republic of Vietnam and its implementing guidelines;
- Pursuant to the Law on Securities of the Socialist Republic of Vietnam and its implementing guidelines;
- Pursuant to the Charter of Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company, amended and supplemented for the 12th time according to the Resolution of General Meeting of Shareholders dated June 26, 2024 ;

RESOLVES:

Article 1: The following content is unanimously approved:

- 1. Meeting time :** The 2026 Annual General Meeting of Shareholders will open at 8:30 AM, Friday, June 26, 2026.
 - Venue for the Meeting: In Hanoi (surveying suitable locations for holding the meeting).
 - Shareholder Record date: May 28, 2026
- 2. Presentation of the agenda for the Meeting:**
 - Report of the Board of Directors on the operational results of the Board of Directors in 2025 and the implementation plan for 2026;
 - Report of the Board of Management on the 2025 business performance and the implementation plan for 2026;
 - Report of the Board of Supervisors on its supervisory and operational activities in 2025 and the operational direction for 2026;
 - Approval of the audited 2025 Financial Statements;
 - Selection of the independent auditor for the 2026 Financial Statements;
 - Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026;
 - Approval of the remuneration of the Board of Directors and the Board of Supervisors for 2026;
 - Approval of the dismissal of a member of the Board of Directors and the election of an additional member of the Board of Directors;
 - Other matters within the authority of the General Meeting of Shareholders.



Article 2: Effectiveness and Enforcement:

This resolution takes effect from the date of signing. The Board of Directors, the Board of Management, and all relevant individuals and departments are responsible for its implementation.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**



Recipients:

- As mentioned;
- Stored: Secretaty.

Nguyen Ngoc Xuan Trang

